Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It is named after Dr. James Parkinson, the physician who first described the condition in 1817. Parkinson’s disease develops as a result of the degeneration and loss of dopamine-producing cells in a region of the brain called the substantia nigra.
The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for Parkinson’s disease, but various treatment approaches aim to manage symptoms and improve quality of life. Medications, such as levodopa and dopamine agonists, can help replenish dopamine levels or mimic its effects. Physical therapy, occupational therapy, and speech therapy can assist with mobility, daily activities, and communication. In some cases, deep brain stimulation (DBS) surgery may be recommended to alleviate symptoms.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Parkinson’s Disease.
-
Publication date: Apr 19, 2025 Parkinson’s Disease is characterized by selective degeneration of dopaminergic neurons, ...
-
Modulation of premotor cortex excitability mitigates the behavioral and electrophysiological abnormalities in a Parkinson’s Disease Mouse Model.
Publication date: Apr 19, 2025 The subthalamic nucleus (STN) plays a crucial role in suppressing ... -
Sarcopenia in Parkinson’s disease: From pathogenesis to interventions.
Publication date: Apr 19, 2025 Parkinson’s disease (PD) and sarcopenia are prevalent age-related conditions that ... -
Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.
Publication date: Apr 21, 2025 Studies from various countries raise concerns on the association between ... -
Association of OFF period characteristics with patient communication behaviors in Parkinson’s Disease.
Publication date: Apr 21, 2025 Underreporting of OFF symptoms and poor patient-provider communication are known ... -
Exploring the therapeutic potential of NLRP3 inhibitors in Parkinson’s Disease: a systematic review of in-vivo studies.
Publication date: Apr 21, 2025 Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor ... -
Keeping an eye on Parkinson’s disease: color vision and outer retinal thickness as simple and non-invasive biomarkers.
Publication date: Apr 21, 2025 Over the last two decades, visual symptoms and retinal changes ... -
Self-Perception of Drooling Impact in People with Parkinson’s Disease: A Case-Control and Cross-Sectional Study.
Publication date: Apr 21, 2025 Drooling, defined as the involuntary loss of saliva from the ... -
An Implantable In-Hydrogel Wireless Supercapacitor-Activated Neuron System Enables Bidirectional Modulation.
Publication date: Apr 21, 2025 The bidirectional modulation of cerebral neurons in the brain possesses ... -
Comparison of phage and plasmid populations in the gut microbiota between Parkinson’s disease patients and controls.
Publication date: Apr 21, 2025 The aging population worldwide is on the rise, leading to ... -
Eye movement abnormalities in Parkinson’s disease motor subtypes: a video-oculographic study.
Publication date: Apr 21, 2025 Eye movement dysfunction has been described in Parkinson’s disease (PD), ... -
Parkinson’s disease with possible REM sleep behavior disorder correlated with more severe glymphatic system dysfunction.
Publication date: Apr 21, 2025 This study aimed to evaluate the glymphatic system activity in ... -
Serum sirtuin 3 levels and multimodal abnormalities in brain structure and function in parkinson’s disease patients with depression.
Publication date: Apr 21, 2025 Depression is a common nonmotor symptom in patients with Parkinson’s ... -
Microstructure is associated with motor outcomes following Deep Brain Stimulation in Parkinson’s disease.
Publication date: Apr 21, 2025 Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an ... -
Electromagnetized MXenes Enhance the Efficient Direct Reprogramming of Dopamine Neurons for Parkinson’s Disease Therapy.
Publication date: Apr 21, 2025 MXenes, a two-dimensional transition metal carbide and nitride, have shown ... -
Principles and Operation of Virtual Brain Twins.
Publication date: Apr 21, 2025 Current clinical methods often overlook individual variability by relying on ... -
Gentiopicroside Attenuated Dopaminergic Neurodegeneration via Inhibiting Neuroinflammatory Responses and Ferroptosis in Experimental Models of Parkinson’s Disease.
Publication date: May 01, 2025 Along with the hallmark of α-synuclein deposition, neuroinflammation and iron ... -
Targeting dopaminergic neuronal death: Luteolin as a therapeutic modulator in Parkinson’s disease.
Publication date: May 01, 2025 Understanding the convoluted roles of dopamine in brain function is ... -
Caregiving Activities and Outcomes Among Family Caregivers of Individuals With and Without Parkinson’s Disease and Lewy Body Dementia in California Caregiver Resource Centers.
Publication date: Apr 23, 2025 To describe characteristics and outcomes of family caregivers for persons ... -
Stem Cell Therapies Could Treat Parkinson’s Disease by Rebuilding Lost Circuitry in the Brain, Studies Suggest
Publication date: Apr 22, 2025 A treatment that could replenish cells in the brains of ... -
One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson’s Disease
Publication date: Apr 12, 2025 This study compares the effects of deep brain stimulation (DBS) ...